Is Gennex Lab. overvalued or undervalued?

As of 7 November 2025, Gennex Lab. has moved from a very attractive to an attractive valuation grade. The company is currently considered overvalued based on its valuation metrics. Key ratios include a PE ratio of 19.66, an EV to EBITDA of 13.64, and a PEG ratio of 1.49, which suggest that the stock is priced higher relative to its earnings growth potential compared to peers. In comparison to its peers, Gennex Lab. has a lower PE ratio than Sun Pharma. (35.17) and Divi's Lab. (71.11), both of which are categorized as expensive. However, it is higher than Cipla's PE of 22.33 and Dr. Reddy's Labs at 17.43, both of which are rated attractive. Despite a recent decline in stock performance, with a year-to-date return of -12.73% compared to the Sensex's 6.50%, the valuation metrics indicate that Gennex Lab. is not positioned favorably in the current market environment.